Despite improvements in pharmacological therapy and pacing, prognosis in advanced heart failure (HF) remains poor, with a 1-year mortality of 25-50%. While heart transplantation provides excellent survival and quality of life for eligible patients, only a few can be offered this treatment due to shortage of donor organs. Implantable left ventricular assist device (LVAD) technology has improved considerably, and the currently used continuous flow devices may last >10 years in a patient. LVADs are being used increasingly both as bridge-to-transplantation and as destination therapy. Current studies report 1-and 2-year survival after LVAD implantation of 80% and 70%, respectively. Outcome after LVAD implantation in stable patients is superior to that of 'crash and burn' patients or patients sliding on inotropes, favouring early referral and implantation. This review summarizes factors to consider when deciding on LVAD implantation such as age, co-morbidity, and cardiac pathophysiology. Complications to LVAD therapy are reviewed. It is concluded that while complications with LVAD therapy are not uncommon, most are manageable, and current outcomes clearly justify use of LVADs in advanced HF.
Introduction
Use of evidence-based medical therapy, advanced pacemakers, and implantable defibrillators has changed prognosis in heart failure (HF) dramatically. However, 0.5-5% of patients respond poorly to standard therapy and develop chronic advanced HF.
1,2 Data from the USA suggest that 250 000-300 000 patients younger than 75 years suffer from advanced systolic HF (defined as NYHA class IIIb-IV). Extrapolating these figures to Europe would equate to a population of 500 000 patients in the EU. Prognosis in advanced HF is grave, with a 1-year mortality in ambulatory class III-IV patients >25% and exceeding 50% in class IV patients. 3, 4 While palliative care is the treatment of choice for patients of advanced age or patients burdened with significant co-morbidity, advanced therapies, such as heart transplantation or a left ventricular assist device (LVAD), must be considered in the rest. Heart transplantation is an excellent treatment option for many patients, but suitable donor availability is extremely limited. Implantable LVADs have been used for decades in very advanced HF or cardiogenic shock primarily as a bridge to heart transplantation. Improvements in technology, especially the advent of smaller, durable continuous flow (CF) pumps, coupled with a shortage of donor hearts for transplantation, have led to use of LVADs in a much broader population of patients in the last 10 years. The aim of this state-of-the-art review, targeting LVAD non-expert internists and cardiologists caring for HF patients, is to describe current standards for patient selection and management with respect to LVAD therapy and to summarize current outcome data.
Left ventricular assist device technology and use
For the last decade, the vast majority of patients treated with an implantable LVAD received a CF device, either a centrifugal pump such as the HeartWare HVAD (Medtronic, St. Paul, MN, USA) or an axial flow pump such as the HeartMate II (St. Jude Medical, Minneapolis, MN, USA; Figure 1) . Recently a new generation of magnetically levitated centrifugal pumps (HeartMate III, St. Jude Medical) has successfully completed a CE mark study and is available in Europe. Irrespective of design, the pumps unload the heart by pumping blood from the left ventricle to the ascending aorta. Contemporary LVADs are driven electrically via a percutaneous driveline connected to a small computer (controller) and external energy source, either batteries that are replaced every 4-12 h depending on the pump model or an AC power source. The pumps generate up to 10 L/min of flow, and as flow is continuous most patients have an undetectable peripheral pulse or a very small pulse pressure. The HeartMate III has a pump speed variability algorithm creating a small artificial pulse every 2 s that may improve washing of the blood-contacting surfaces of the device. While the original pulsatile pumps had a limited life span, in most cases of <2 years, the CF devices may last >10 years. In the USA, implantation rates are monitored by a widely used registry, INTERMACS. Currently, >2500 pumps are implanted in the USA every year, and it is clear that a linear increase has taken place since 2006 ( Figure 2) . Similar data for Europe are not available, but it is estimated that ∼2000 pumps are implanted annually.
Patient selection and timing
Historically LVADs were used for shorter periods of time to ensure survival of younger patients until a donor organ became available, so-called bridge-to-transplantation (BTT). 5 Since publication of the REMATCH trial in 2001 that demonstrated improved survival in advanced HF patients ineligible for transplantation treated with LVAD vs. optimal medical therapy, a growing number of patients have received LVADs as a permanent treatment or 'destination therapy' (DT). 6 Another cohort of LVAD patients is comprised of those referred for transplantation with relative contraindications or co-morbidities that may be reversible after a more prolonged period of haemodynamic support. This group has been designated bridge-to-decision (BTD Whereas guidelines for heart transplant listing exist, 8 there are no universally accepted criteria for LVAD implantation.
9 -11 Some commonly used indicators of illness severity include an EF ≤25%, frequent or prolonged HF hospitalizations, inability to tolerate standard HF treatments secondary to hypotension or renal insufficiency, and reduced maximal or submaximal exercise performance. Heart transplant listing criteria are important considerations in determining LVAD candidacy, but there are important distinctions between candidates for the treatments. For instance, pulmonary hypertension or recent cancer are important relative contraindications for transplantation but not for LVAD therapy, whereas patients with complex congenital heart disease or significant right ventricular (RV) failure are less optimal LVAD candidates while they may experience good outcomes with transplantation. Most centres rely on the criteria used in clinical trials leading to Food and Drug Administation (FDA) approval to define DT candidates coupled with haemodynamic derangement including low cardiac index (<2.2 L/min/m 2 ) and/or elevated left-sided filling pressures ( Table 1 ).
An important contribution to the process of patient selection for LVAD was the emergence of the INTERMACS classification.
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It is clear that the spectrum of patients with advanced HF (NYHA III-IV) is wide, from housebound patients with poor exercise capacity and patients who remain stable despite frequent admissions with fluid overload, to patients dying from cardiogenic shock despite inotropic support within days or hours. These clinical scenarios are captured in the INTERMACS patient profiles. In short, INTERMACS profiles 1-3 describe inotrope-dependent 
Table 1 Main inclusion criteria for HeartMate II destination therapy (HM2-DT) trial
NYHA IIIb-IV symptoms for at least 45 of the last 60 days. HF symptoms failed to respond to optimal medical management. LVEF <25%. Peak VO 2 < 14 mL/kg/min or continued need for i.v. inotropic therapy owing to symptomatic hypotension, decreasing renal function, or worsening pulmonary congestion. I.v. inotropic medications for ≥14 days. Intra-aortic balloon pump support for ≥7 days.
patients from the 'crash and burn' (INTERMACS 1) to patients stable on inotrope infusion (INTERMACS 3), and 4-7 cover non-inotrope-dependent patients with different levels and types of advanced HF symptoms.
Registry data have shown that outcomes after LVAD implantation are inferior for patients in INTERMACS 1-2. As a result, many LVAD programmes either do not implant durable LVADs in these patients or use alternative strategies to improve clinical stability such as temporary mechanical circulatory support. Outcomes in INTERMACS 3 (stable on inotropes) are better than in class 1-2 and this has traditionally been advocated as the optimal group for implantation of durable LVADs. Retrospective analyses suggest that survival rate is even better in non-inotrope-dependent HF, 13, 14 and the prospective ROADMAP study demonstrated superior survival with improvements in submaximal exercise performance in INTER-MACS profile 4-7 patients treated with LVAD (HeartMate II) compared with patients treated medically. 15 In this study of patients with at least one recent HF hospitalization and a 6-min walk test distance <300 m, a higher frequency of adverse events was noted in the LVAD group, but nevertheless it supports a strategy of early implantation. 
16,17
While these risk scores are useful to identify patients at very high operative risk, and, in turn, patients in whom LVAD implantation may be futile, they do not provide guidance on whether the individual HF patient may benefit from the intervention and should not be relied upon as sole instruments for patient selection.
Early referral for evaluation in an LVAD or transplant centre is essential. Clinical identification of patients with early advanced HF remains challenging. We recommend referral or at least discussion of patients who remain in NYHA III despite optimal medical therapy and CRT if needed. Some easily identifiable characteristics for high-risk individuals have been proposed and may facilitate a rational referral pattern: inability to walk one block, hyponatraemia, significant renal dysfunction, inability to tolerate ACE inhibitors, ARBs, or beta-blockers, high doses of diuretics, anaemia, recent HF admissions, or lack of response to CRT.
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Specific considerations relating to left ventricular assist device candidacy Age
Advanced age is not a contraindication to LVAD therapy per se, but many elderly patients have multiorgan dysfunction, frailty, or other significant co-morbidity that may compromise outcomes. Indeed, age is a potent risk factor for mortality or prolonged hospitalization after LVAD implantation. 19, 20 However, several centres have experience in treating elderly patients. In a study including 30 patients >70 years (and six >80 years) a 70% 3-year survival, which was not different from that observed in patients <70 years, was found. 21 Hence, carefully selected elderly patients can undergo LVAD implantation and experience excellent survival. Social support is crucial in LVAD patients, especially elderly or fragile patients.
Aortic valve regurgitation
Untreated significant aortic regurgitation (AR) is a contraindication to LVAD implantation as it prevents pump flow from contributing to organ perfusion. AR may be corrected at the time of LVAD implantation either by valve replacement using a bioprosthesis or by oversewing the valve. Results regarding outcome after LVAD implantation requiring aortic valve intervention are conflicting, 22, 23 and some centres consider significant AR a relative contraindication to LVAD implantation or at least a factor which must be weighed in the overall operative risk.
Right ventricular function
While residual left heart function is not crucial to the circulatory system following LVAD implantation, RV function must be able to overcome pulmonary vascular resistance to ensure LV and, in turn, pump filling to maintain systemic circulation. Numerous predictors of post-LVAD RV failure have been identified, 24 -27 but there is no consensus on measures of RV function that would constitute an absolute contraindication to LVAD implantation. Importantly, RV function should be evaluated (or re-evaluated) after adequate correction of fluid overload. Pre-operative evaluation of RV function on inotropic drugs or temporary mechanical circulatory support may lead to underestimation of RV dysfunction. Fairly consistent pre-operative risk factors for development of severe RV failure post-LVAD implantation as identified in the larger studies are elevated central venous pressure (CVP) (or CVP/PCWP ratio), severe renal dysfunction, and ventilator dependence. Specific echocardiographic measures of RV function have exhibited poor reproducibility across studies and should probably not per se exclude patients from LVAD implantation. Late RV failure after LVAD implantation clearly occurs, probably due to progressive cardiomyopathy or an increase in RV afterload, but is not yet well described. It manifests as recurrence of HF symptoms and fluid overload. 28 
Ventricular arrhythmias
Ventricular tachyarrhythmias (VTs) may improve after LVAD implantation, presumably because of LV unloading, but LVAD implantation per se may also be associated with increased tendency to VT. While VT/ventricular fibrillation (VF) compromises RV function, VT/VF may be tolerated quite well in LVAD recipients depending on the pulmonary vascular resistance and CVP, 29 but may induce haemodynamic instability in some patients. 30, 31 Patients with LV dysfunction, who are mainly haemodynamically unstable because of recurrent VT, should be treated with ablation, antiarrhythmics, or, ultimately, a biventricular assist device (BiVAD), a total artificial heart, or transplantation rather than . 
Congenital cardiac defects
Simple cardiac malformations such as atrial septal defects can be repaired at the time of LVAD implantation without significantly increased peri-operative mortality. 23 LVAD implantation in patients with complex congenital heart disease has been reported, but remains experimental.
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Infection
Active systemic bacterial or fungal infection is a contraindication to LVAD implantation, whereas localized and controlled infections (such as a treated urinary tract infection) typically should not delay surgery. Also, some well-controlled chronic viral infections such as HCV or HIV will not necessarily impact outcomes. 34 
Bleeding disorders
Implantable LVADs require anticoagulation to avoid pump thrombosis, typically a vitamin K antagonist targeting an international normalized ratio (INR) between 2 and 2.5 and an antiplatelet agent. 35 -37 In addition, it is well described that CF-LVADs are associated with acquired von Willebrand disease due to device-related shear stress affecting the macromolecular form of von Willebrand factor. 38 This leads to a significant bleeding risk after implantation; hence, other sources of compromised haemostasis (genetic bleeding disorders, severe hepatic insufficiency, etc.) will constitute an unacceptably high risk for LVAD implantation. Furthermore, continuous blood flow may lead to formation of arteriovenous malformations especially in the gastrointestinal tract. Arteriovenous malformations predispose to bleeding, may be difficult to diagnose and treat, and hence are a cause of morbidity in LVAD recipients. 39 
Renal dysfunction
In many patients with advanced HF, even significant azotaemia is related to cardiorenal syndrome rather than intrinsic kidney disease, and several studies have documented that renal function improves in most patients following LVAD implantation. 40 Even if renal dysfunction is a risk factor for post-operative RV failure, it is not an absolute contraindication to LVAD therapy. Patients with nephropathy and high grade proteinuria or renal atrophy on ultrasound examination may be at very high risk, and few centres would accept patients on chronic dialysis because of the risk of device infection and overall risk of poor outcome. 
Psychosocial considerations
As is the case for heart transplant candidates, patients undergoing LVAD implantation must be motivated and compliant with medical therapy and follow-up. Substance abuse or alcoholism contraindicate LVAD therapy. Patients living alone may do well with an LVAD, but studies have documented that social network and even marital status are important factors in achieving good outcomes with LVAD therapy. 41 Depression and dementia are very common in advanced HF 42 and, although depression typically improves after LVAD implantation, 43 both are important to recognize prior to implant decision. Evidently, this array of psychosocial factors is of utmost importance and must be considered for all LVAD candidates. A team approach to evaluation of these issues as well as to the subsequent implant decision is highly recommended.
Outcome Survival
Survival after CF-LVAD implantation has improved significantly over the last decade. Data from the most recent analysis from the US INTERMACS registry of CF-LVADs show a 1-year survival of 80% and a 2-year survival of 70%. 18, 19 Slightly lower survival rates have been reported by the European EUROMACS registry (survival 73, 63, and 61% at 1, 2, and 3 years, respectively). 44 In the ENDURANCE DT randomized trial (n = 446), 2-year survival with HVAD and HeartMate II was 60% and 68%, respectively (P = 0.17). 45 It is anticipated that outcome will continue to improve with the development of newer generation LVADs. Recently published results from the CE mark study of the first 50 patients implanted with the HeartMate III revealed a 6-month survival of 92%. 47 Data from the first 294 patients randomized in the MOMEMTUM trial comparing outcomes with HeartMate III vs. HeartMate II recently showed a 6-month survival of 89% and 87% in the HeartMate III and HeartMate II groups, respectively. 48, 49 Several risk factors for early mortality after LVAD implantation have been identified including advancing age, female gender, obesity, INTERMACS 1-2, renal dysfunction, elevated bilirubin, and previous or need for concomitant cardiac surgery.
17 -19 A better understanding of these factors combined with technologically optimized pumps together with improved medical care for this complex patient group should pave the way for even better prognosis in the coming decade.
Morbidity
While the incidence of complications has decreased substantially with the advent of modern CF-LVADs, adverse events are not uncommon. Stroke (haemorrhagic and ischaemic), bleeding (especially gastrointestinal), arrhythmia, and driveline exit site infection are common causes of post-LVAD morbidity. An overview of complication rates from major CF-LVAD trials is given in Table 2 . Driveline exit site infection is a particularly common complication, representing a burden for patient and caregiver. Occurrence of driveline infections in studies ranges from 20% to 60% of patients; fortunately most remain superficial and can be managed with antibiotics. 50 -52 Infection and antibiotics for driveline infection may, however, interfere with anticoagulation therapy and increase the risk of thrombotic events or bleeding, and have been associated with increased mortality in some studies. 51 It is imperative to obtain exit site swabs and blood cultures when driveline infections are suspected. Ultrasound or computed tomography scans may be necessary to reveal ascending driveline or pump pocket infections. New strategies to prevent driveline infections appear to reduce the risk significantly, as recently demonstrated. 53 While the incidence of exit site driveline infections appears to have decreased, 54 other important complications have remained reasonably stable over time. As a consequence, readmission rates after LVAD implantation are not trivial, ranging in different studies from 1.3 to 2.6 hospitalizations per patient-year.
15,55 -58 Pump thrombosis and need for pump exchange have been a problem of considerable magnitude in CF devices, leading to increased morbidity, costs, and mortality. 35, 36 Routine monitoring of haemolysis markers such as plasma haemoglobin and lactate dehydrogenase is recommend to allow for early detection of pump (or inflow or outflow graft) thrombosis. With new magnetically levitated devices, this risk may be substantially reduced, although long-term data are still needed to confirm this. 48 
Functional capacity and quality of life
Heart failure symptoms are clearly reduced after LVAD implantation, and the vast majority (>80%) of patients have NYHA functional class I-II limitations within 3 months of implantation.
15,59
Accordingly, several studies have consistently documented that LVAD implantation is associated with a substantial increase in 6-min walk test distance and measures of quality of life. 57, 59, 60 In contrast, maximal oxygen uptake (pVO 2 ) remains significantly reduced after LVAD implantation, probably reflecting that pump technology might not result in optimal support during exercise in current LVADs 61, 62 and clearly also that pVO 2 in HF is influenced by multiple non-cardiac factors. 63 More knowledge about pump physiology during exercise, medical management, and physical rehabilitation in these patients is evidently needed.
Conclusion and future directions
Continuos flow LVADs improve survival of deteriorating HF patients waiting for heart transplantation and also for patients with advanced HF who are not transplant candidates. Short and intermediate survival after LVAD implantation has improved over the last decade and is clearly superior to medical therapy. Early implantation, and avoiding implantation in INTERMACS 1-2 patients with co-morbidity, is advised for best outcomes. Adverse events are common, but incidence seems to be declining, at least the risk of driveline infections. While further technical developments are awaited, especially a low energy consuming, fully implantable pump, it should be recognized that LVAD implantation is an established life-saving therapy of today not an experimental intervention for tomorrow. 
